CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC

Smoking Ban in Austria Passed After Years of Political Wrangling

Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

New FDA Commissioner Confirmed

Dr. Chandra P. Belani Named New Chief Science Officer for the IASLC

Multidisciplinary Teams at AUSL Romagna

Rebuilding Choice Architecture for Incurable but Treatable Lung Cancer: Rethinking the Future of Hospice Care in the United States

PD-L1 in Cytology Specimens

A Balancing Act: Managing Patients’ Expectations

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

STARS Patient Research Advocate Training Program Seeks Patients and Caregivers

Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint Blockage in NSCLC